Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma

Lung Cancer

Volumn 67, Issue 3, 2010, Pages 311-317

  Veit Haibach, Patrick ^a   Schaefer, Niklaus G ^a   Steinert, Hans C ^a   Soyka, Jan D ^a   Seifert, Burkhardt ^b   Stahel, Rolf A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

EORTC criteria; Mesothelioma; PET volume; PET CT; RECIST criteria; Survival; Therapy response assessment; Tumor lesion glycolysis

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUORODEOXYGLUCOSE; PEMETREXED;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; GLYCOLYSIS; HUMAN; IMAGE ANALYSIS; MALIGNANT MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT MONITORING; PLEURA MESOTHELIOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; FEMALE; FLUORODEOXYGLUCOSE F18; GLUTAMATES; GLYCOLYSIS; GUANINE; HUMANS; MALE; MESOTHELIOMA; PALLIATIVE CARE; PLEURAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; TREATMENT OUTCOME;

EID: 75749132383     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.04.015     Document Type: Article

References (28)

1. Peli J., Schroter M., Rudaz C., Hahne M., Meyer C., Reichmann E., et al. Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. EMBO J 18 (1999) 1824-1831
2. Pelucchi C., Malvezzi M., La Vecchia C., Levi F., Decarli A., and Negri E. The mesothelioma epidemic in Western Europe: an update. Br J Cancer 90 (2004) 1022-1024
3. Ceresoli G.L., Betta G.P., Castagneto B., Facciolo F., Arcangeli G., Zucali P.A., et al. Malignant pleural mesothelioma. Ann Oncol 17 Suppl. 2 (2006) ii13-ii16
4. Andreopoulou E., Ross P.J., O'Brien M.E., Ford H.E., Priest K., Eisen T., et al. The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Ann Oncol 15 (2004) 1406-1412
5. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Gatzemeier U., et al. Phase III study of pemetrexed in combination with cisplatin vs cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol (2003) 2636-2644
6. van Meerbeeck J.P., Gaafar R., Manegold C., Van Klaveren R.J., Van Marck E.A., Vincent M., Legrand C., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23 (2005) 6881-6889
7. Weder W., Stahel R.A., Bernhard J., Bodis S., Vogt P., Ballabeni P., et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 18 (2007) 1196-1202
8. Sugarbaker D.J., Garcia J.P., Richards W.G., Harpole Jr. D.H., Healy-Baldini E., DeCamp Jr. M.M., et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg 224 (1996) 288-294
9. Oxnard G.R., Armato III S.G., and Kindler H.L. Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer 52 (2006) 141-148
10. Plathow C., Klopp M., Thieke C., Herth F., Thomas A., Schmaehl A., et al. Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT. Eur Radiol 18 (2008) 1635-1643
11. van Klaveren R.J., Aerts J.G., de Bruin H., Giaccone G., Manegold C., and van Meerbeeck J.P. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer 43 (2004) 63-69
12. Byrne M.J., and Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15 (2004) 257-260
13. Plathow C., Klopp M., Thieke C., Herth F., Thomas A., Schmaehl A., et al. Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT. Eur Radiol 18 (2008) 1635-1643
14. Carretta A., Landoni C., Melloni G., Ceresoli G.L., Compierchio A., Fazio F., et al. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases-a pilot study. Eur J Cardiothorac Surg 17 (2000) 377-383
15. Ceresoli G.L., Chiti A., Zucali P.A., Rodari M., Lutman R.F., Salamina S., et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol 24 (2006) 4587-4593
16. Francis R.J., Byrne M.J., van der Schaaf A.A., Boucek J.A., Nowak A.K., Phillips M., et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 48 (2007) 1449-1458
17. Steinert H.C. Lung cancer. Recent Results Cancer Res 170 (2008) 81-92
18. Steinert H.C., Santos Dellea M.M., Burger C., and Stahel R. Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging. Lung Cancer 49 Suppl 1 (2005) S33-35
19. AJCC. AJCC cancer staging manual (2002), Springer, Stuttgart/Heidelberg/New York
20. Akhurst T., Ng V.V., Larson S.M., O'Donoghue J.A., O'Neel J., Erdi Y., et al. Tumor burden assessment with positron emission tomography with. Clin Positron Imaging 3 (2000) 57-65
21. Larson S.M., Erdi Y., Akhurst T., Mazumdar M., Macapinlac H.A., Finn R.D., et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 2 (1999) 159-171
22. Melton G.B., Lavely W.C., Jacene H.A., Schulick R.D., Choti M.A., Wahl R.L., et al. Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy. J Gastrointest Surg 11 (2007) 961-969 [discussion 969]
23. Young H., Baum R., Cremerius U., Herholz K., Hoekstra O., Lammertsma A.A., et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35 (1999) 1773-1782
24. Robinson B.W., Musk A.W., and Lake R.A. Malignant mesothelioma. Lancet 366 (2005) 397-408
25. Sugarbaker D.J., Flores R.M., Jaklitsch M.T., Richards W.G., Strauss G.M., Corson J.M., et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117 (1999) 54-63 [discussion 63-55]
26. Flores R.M., Akhurst T., Gonen M., Larson S.M., and Rusch V.W. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 126 (2003) 11-16
27. Ahmadzadehfar H., Palmedo H., Strunk H., Biersack H.J., Habibi E., and Ezziddin S. False positive 18F-FDG-PET/CT in a patient after talc pleurodesis. Lung Cancer 58 (2007) 418-421
28. Kwek B.H., Aquino S.L., and Fischman A.J. Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis. Chest 125 (2004) 2356-2360